Feed Top Reports Pricing

⌘K

07:31:11·50d

SECFiling

SEC Form 10-K filed by Kura Oncology Inc.

KURA· Kura Oncology Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

KURA
Kura Oncology Inc.
Health Care

Recent analyst ratings

Apr 14UpdateLake Street$23.00
Sep 4UpdateGuggenheim-
Feb 6UpdateBTIG Research-
Oct 24UpdateUBS$27.00
Oct 14UpdateStifel$19.00
Dec 22UpdateMizuho$26.00

Related

PR1h
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
PR7d
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
ANALYST10d
Lake Street initiated coverage on Kura Oncology with a new price target
SEC13d
SEC Form DEFA14A filed by Kura Oncology Inc.
SEC13d
SEC Form DEF 14A filed by Kura Oncology Inc.
PR15d
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
PR21d
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEC27d
Amendment: SEC Form SCHEDULE 13G/A filed by Kura Oncology Inc.

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022